FDAnews Drug Daily Bulletin

While the Affordable Care Act (ACA) is generally a revenue boon for drugmakers, the law presents pricing and formulary pressures that will force companies to steer toward less-saturated disease areas and better show the value of their products, experts say. Biopharma innovators are already changing gear as more of their patents expire but the Supreme Court’s landmark ruling upholding the healthcare law is a “catalyst” to drive drugmakers toward a lower-cost, higher-quality environment, Ralph Marcello, a principal at Deloitte Consulting’s life sciences practice, said Thursday.
Drug Industry Daily